Evidence map›Paper›PMID 35677165›Full record

ArticleFrontiers in oncology2022

Discovery of Novel Tetrahydro-β-carboline Containing Aminopeptidase N Inhibitors as Cancer Chemosensitizers.

Xiaoyan Xing, Fahui Li, Yajie Hu, Lin Zhang, Qian Hui, Hongyu Qin, Qixiao Jiang, Wenyan Jiang, Chunyan Fang, Lei Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Xiaoyan XingDepartment of Pharmacology, School of Pharmacy, Weifang Medical University, Weifang, China.
Fahui LiDepartment of Medicinal Chemistry, School of Pharmacy, Weifang Medical University, Weifang, China.
Yajie HuDepartment of Medicinal Chemistry, School of Pharmacy, Weifang Medical University, Weifang, China.
Lin ZhangDepartment of Medicinal Chemistry, School of Pharmacy, Weifang Medical University, Weifang, China.
Qian HuiDepartment of Medicinal Chemistry, School of Pharmacy, Weifang Medical University, Weifang, China.
Hongyu QinDepartment of Medicinal Chemistry, School of Pharmacy, Weifang Medical University, Weifang, China.
Qixiao JiangDepartment of Toxicology, School of Public Health, Qingdao University, Qingdao, China.
Wenyan JiangDepartment of Medicinal Chemistry, School of Pharmacy, Weifang Medical University, Weifang, China.
Chunyan FangDepartment of Pharmacology, School of Pharmacy, Weifang Medical University, Weifang, China.
Lei ZhangDepartment of Medicinal Chemistry, School of Pharmacy, Weifang Medical University, Weifang, China.
Weifang Medical University · CNQingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aminopeptidase N (APN, CD13) is closely associated with the development and progression of cancer. Previous studies suggested APN as a biomarker for cancer stem cells. APN inhibitors have been intensively evaluated as chemosensitizers for cancer treatments. In the present study, tetrahydro-

Indexed as

aminopeptidase Ncancerchemosensitizerinhibitortetrahydro-β-carboline

Identifiers

PMID35677165
PMCPMC9168271
OpenAlexW4281297886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.